Panobinostat inhibits HDAC, which causes cell cycle arrest and apoptosis, and clinical trials have shown the use of Panobinostat in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma [62]. Here, HDAC9 is linked to plasma cell myeloma.